Dear University of Auckland,
This request is to Ms Petoussis Harris under your employ who recently gave evidence at the royal Covid enquiry last week. She said that the vaccine and its associated manufactured spike proteins break down in a couple of days in the human body.
This information request is to her:
I note that the product Comirnaty which Medsafe approved has the following description on its data sheet:
"The active ingredient is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ".

1. Is the messenger ribonucleic acid or mRNA a genetic material?
2. What is the excretion and half-life of this active ingredient?
3. When does the messenger ribonucleic acid cease to give instructions to DNA in the human recipient?

Yours faithfully,

Erika Whittome

Dear University of Auckland & Ms Petoussis-Harris,

COVID-19 mRNA and adenoviral vector products function by delivering genetic instructions to human cells, which then produce foreign proteins (like the SARS-CoV-2 spike protein). This mechanism directly aligns with the FDA's own definitions of "gene therapy products."

The FDA has established the regulatory definition of gene therapy products through its authoritative guidance documents, specifically: "Guidance for Human Somatic Cell Therapy and Gene Therapy" (1998), which states that
"Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use," and "Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications" (2020), which defines gene therapy products as those that "mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome." These guidance documents are binding on the FDA under the Accardi doctrine, United States ex rel. Accardi v. Shaughnessy, 347 U.S. 260 (1954), which prohibits agencies from departing from their own established rules, procedures, or interpretive frameworks without adequate justification.
See United States ex rel. Accardi v. Shaughnessy, 347 U.S. 260 (1954).
(From
https://www.regulations.gov/document/FDA...)

Yours faithfully,

Erika Whittome